目的 探讨乳块消颗粒联合溴隐亭治疗乳腺增生的临床疗效。方法 回顾性分析2020年1月-2022年12月在海口市妇幼保健院治疗的120例乳腺增生患者临床资料。根据用药种类的不同分为对照组和治疗组,每组各60例。对照组口服甲磺酸溴隐亭片,2.5 mg/次,2次/d;在此基础上,治疗组口服乳块消颗粒,10 g/次,3次/d。两组患者经8周治疗。观察两组患者临床疗效,比较治疗前后两组患者临床症状评分,乳腺肿块直径、腺体层厚度、输乳管内径和低回声区直径,及雌二醇(E₂)、泌乳素(PRL)、孕酮(P)、p53、血管内皮生长因子(VEGF)和转化生长因子-β1(TGF-β1)水平。结果 治疗后,治疗组临床总有效率为98.33%,明显高于对照组(83.33%,P<0.05)。治疗后,两组患者乳痛评分、肿块硬度评分、肿块范围评分、肿块大小评分均明显降低(P<0.05),并以治疗组下降最为显著(P<0.05)。治疗后,两组乳腺肿块直径、腺体层厚度、输乳管内径、低回声区直径均明显减小(P<0.05),并以治疗组减小最为显著(P<0.05)。治疗后,两组E₂、PRL、p53、VEGF、TGF-β1表达明显降低,而P水平明显升高(P<0.05),且治疗组改善最为显著(P<0.05)。结论 乳块消颗粒联合溴隐亭治疗乳腺增生可有效改善患者症状,促进乳腺结构、形态改善,调节机体性激素及细胞因子表达。

Objective Explore the clinical efficacy of Rukuaixiao Granules combined with bromocriptine in treatment of breast hyperplasia. Methods The clinical data of 120 patients with breast hyperplasia treated in Haikou Hospital of the Maternal and Child Health from January 2020 to December 2022 were analyzed retrospectively, and they were divided into control group and treatment group according to the types of drugs, each group had 60 cases. Patients in the control group were po administered with Bromocriptine Mesilate Tablets, 2.5 mg/time, twice daily. Patients in the treatment group were po administered with Rukuaixiao Granules on the basis of the control group, 10 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluation was evaluated, and the clinical symptom scores, diameter of breast mass, thickness of glandular layer, inner diameter of breast duct and diameter of hypoechoic area, and the levels of E₂, PRL, p53, VEGF, TGF-β1 and P in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 98.33%, which was significantly higher than that of the control group (83.33%, P < 0.05). After treatment, the scores of breast pain, mass hardness, mass size and mass size were significantly decreased in two groups (P < 0.05), especially in the treatment group (P < 0.05). After treatment, the diameter of breast mass, the thickness of glandular layer, the inner diameter of breast duct and the diameter of hypoechoic area were significantly decreased in two groups (P < 0.05), especially in the treatment group (P < 0.05). After treatment, the expression of E₂, PRL, p53, VEGF and TGF-β1 in two groups were significantly decreased, while the level of P was significantly increased (P < 0.05), especially in the treatment group (P < 0.05). Conclusion Ruduanxiao Granules combined with bromocriptine can effectively improve the symptoms of patients with breast hyperplasia, promote the improvement of breast structure and morphology, and regulate the expression of sex hormones and cytokines.

R984

海南省自然科学基金青年基金项目(821QN426)